Compare Salesforce Inc (CRM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Revvity Inc — how do they compare? Salesforce Inc trades at $193.22 (market cap $161.73B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Salesforce Inc is far larger — about 12.5× Revvity Inc's market cap, and Salesforce Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| CRM | RVTY | |
|---|---|---|
Market Cap | $161.73B | $12.91B |
Sector | Technology | Technology |
52-Week High | $266.23 | $117.75 |
52-Week Low | $150.12 | $82.26 |
Enterprise Value | $191.77B | $15.23B |
Dividend Yield | 0.89% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $192.33, down 2.62% amid broader software sector weakness driven by AI disruption concerns. The stock maintains strong fundamentals with consistent earnings beats, 77.64% gross margins, and 18.73% net income margin. Technical indicators show bullish momentum despite overbought RSI readings, with key support at $193. Analyst consensus remains strongly bullish with a $230.83 price target representing 20% upside potential.
CRM presents a compelling investment case with robust profitability, AI monetization growth, and discounted valuation. Near-term risks include software sector volatility and AI competition, but strong cash flow generation and institutional support provide stability. The current dip offers entry opportunity for long-term investors seeking exposure to enterprise software leadership.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
